Printer Friendly
The Free Library
19,607,053 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Enzo Biochem to Present at Lazard Capital Markets Third Annual Life Sciences Conference.


NEW YORK New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
 -- Enzo Biochem, Inc. (NYSE NYSE

See: New York Stock Exchange
:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, announced today that Barry Weiner, President, will make a presentation on Tuesday, November 28, 2006, at 4:30P.M. (E.T.) at the Lazard Capital Markets Lazard Capital Markets is a New York-based investment bank founded in 2005 in a spin-off from its parent Lazard.

Lazard Capital Markets focuses its activities on equity research, sales and trading; fixed income and convertible bond sales and trading; and securities
 Third Annual Life Sciences Conference, being held at the New York Palace
  • Palace Theatre, New York
  • New York Palace, Budapest, Hungary
 Hotel in New York City New York City: see New York, city.
New York City

City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S.
.

About Enzo

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller  and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis, uveitis uveitis

Inflammation of the uvea, the middle coat of the eyeball. Anterior uveitis, involving the iris or ciliary body (containing the muscle that adjusts the lens) or both, can lead to glaucoma and blindness.
, and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 22, 2006
Words:350
Previous Article:Royce Value Trust, Inc. (NYSE - RVT) Declares Fourth Quarter Common Stock Distribution of $0.50 Per Share.
Next Article:The Bon-Ton Stores, Inc. Announces Quarterly Cash Dividend.
Topics:



Related Articles
ENZO BIOCHEM TREATMENT ALLEVIATES TRANSPLANTATION SIDE EFFECTS.
Enzo Biochem Reports Results for Fourth Quarter and Fiscal Year.
Enzo Biochem Reports Fiscal 2006 First Quarter Operating Results.
Enzo Biochem Shareholders Elect Three Directors at Annual Meeting.
Enzo Biochem Reports Second Quarter Results; HIV-1 Stealth Vector Trial Initiated.
Enzo Biochem to Present at Needham & Company Fifth Annual Biotechnology Conference.
Enzo Biochem Reports Court Ruling.
Enzo Biochem Reports Results for Fiscal 2006 and Fourth Quarter.
Omnicare to Present at Lazard Capital Markets Third Annual Life Sciences Conference and Merrill Lynch Health Services Investor Conference.
Enzo Therapeutics Treats First Patient in Phase I/II Study of Antisense Gene Therapy for HIV-1 Infections.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles